Form 4: Acrivon Therapeutics Director Sharon Shacham Granted Stock Options

Acrivon Therapeutics, Inc. Director Sharon Shacham was granted 20,275 stock options with an exercise price of $1.20 per share, as disclosed in a recent SEC Form 4 filing.

Summary

• Sharon Shacham, a Director of Acrivon Therapeutics, Inc. (ACRV), was granted 20,275 stock options.
• The stock options have an exercise price of $1.20 per share.
• The transaction date for this grant was June 13, 2025.
• The options are set to expire on June 12, 2035.
• The shares subject to the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent upon Ms. Shacham's continuous service through that date.
• Following this transaction, Ms. Shacham directly beneficially owns 20,275 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a standard disclosure of director compensation, which aligns interests but does not inherently indicate significant operational or financial performance changes. The grant itself is a positive for the director and a standard incentive for the company.

Positives

• The grant of stock options to Director Sharon Shacham aligns her interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $1.20 per share provides a clear benchmark for future value creation.

Future Outlook

The granted stock options are subject to a future vesting condition, which will occur on the date immediately preceding the Issuer's next annual meeting of stockholders, provided the reporting person maintains continuous service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation and aligning the interests of directors with those of shareholders.

Corporate Governance

Related Party Transactions

• The grant of 20,275 stock options to Sharon Shacham, a Director of Acrivon Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant is part of the compensation structure for a director, which is a component of the management team.

Next Steps

• The stock options will vest on the date immediately preceding Acrivon Therapeutics' next annual meeting of stockholders, subject to Sharon Shacham's continuous service.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Sharon Shacham, Stock Option Grant, SEC Form 4, Director Compensation, Equity Compensation, Beneficial Ownership, Biotechnology